𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2

✍ Scribed by Rutger L. van Bezooijen; H. Goey; Gerrit Stoter; J. Hermans; G. J. Fleuren

Publisher
Springer-Verlag
Year
1997
Tongue
English
Weight
473 KB
Volume
43
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Metastatic renal-cell carcinoma patients
Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon γ: Immunological monitoring
✍ Françoisc Farace; Marc Pallardy; Eric Angevin; Thierry Hercend; Bernard Escudier 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 737 KB

## Abstract We investigated the biological response of 73 patients with metastatic renal‐cell carcinoma (MRCC) treated by repetitive weekly cycles of high‐dose interleukin 2 (IL‐2) (protocol 1, 40 patients) or IL‐2 plus interferon‐gamma (IFN‐γ) (protocol 2, 33 patients). The objectives of this stud

Prognostic nomogram for sunitinib in pat
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
✍ Robert J. Motzer; Ronald M. Bukowski; Robert A. Figlin; Thomas E. Hutson; M. Dro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 3 views

## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferon‐alfa as first‐line therapy in patients with metastatic clear‐cell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi